Compensation for Victims of Clinical Trials: A Discussion on How Current Indian Rules and Guidelines are Hurting India

Journal of Clinical and Diagnostic Research. 2012 October, Vol-6(8): 1367-1368. DOI: 10.7860/JCDR/2012/4944.2389.

Jacob Puliyel

According to the amended Drugs and Cosmetics Rules of the Government of India, participants in clinical trial are entitled to medical treatment and financial compensation in the event of permanent injury or death, but the quantum of compensation is to be decided by same Ethics Committee that sanctioned the trial in the first place. If there is a dispute regarding the amount of compensation the injured party may appeal again to the Ethics Committee for a review and reconsideration. The decision of the Ethics Committee after the review is final [1].
This editorial discusses the merits of the scheme from the point of view of making India a hub for international clinical research.
Growth of Clinical Trials Industry and Government Ince ntives
In 2002-3 the clinical trials industry in India was worth only US$ 35 million. However it’s potential for growth was recognized [2]. To enable it to reach that potential, the Government of India enacted suitable laws. The previous rules permitted phase 2 trials in India only if phase 3 trials were in progress elsewhere. In January 2005, it allowed foreign pharmaceutical companies to conduct trials in India in the same phase that they were being conducted abroad. Further, to give a fillip to the clinical trial industry, the service tax on clinical trials was withdrawn in 2007–08 [3].
The clinical trial industry responded favorably. It was both easier and cheaper to do a clinical trial in India than in the West. A drug trial in the United States could cost $150 million where as it could be done in India for $ 90 million – 60 per cent of the cost [4]. Recruitment of patients is also much easier in India. Germany’s Mucos Pharma GmbH did a clinical trial for a drug to treat head and neck cancer. The local contract research organisation had to go to only five hospitals in India to recruit 650 out of 750 volunteers for the trial and the local recruitment was complete within 18 months. To recruit the remaining 100 volunteers in Europe, Mucos Pharma spent twice as much time and had to recruit the patients in 22 hospitals [2]. The clinical trials enterprise grew into a US$ 160 industry by 2006-7. According to a report to the Planning Commission in 2008, New Delhi, the market value of clinical trials outsourced to India was expected to touch $1.5-2 billion by 2010 [5].
ultiple Winners
This appeared to be a win–win proposition. Private institutions obtained equipment through joining trials. Pfizer for example donated $100,000 bone density measuring instruments to six hospitals testing its new osteoporosis drug [4]. Investigators in private hospitals were paid recruitment fees of between Rs 60,000 and Rs 120,000 per patient [6]. The principle investigators in government hospitals, who could not accept a recruitment incentive, were given all-expense-paid trips to conferences abroad [6]. Impoverished patients even begged to be included in trials because that was their only affordable means of getting any medical care. The hospitals, the doctors and the patients, all seemed to benefit.
he Downside
In a study 76% of patients in clinical trials said that the principal investigator was their primary physician. Another 21% were referred to the research unit by their primary physician. Thus 97% of those entered trial because of their primary physician. 6 Patients are easily influenced by their doctors . When physicians are paid recruitment fees to recruit their patients to trials, there is a direct conflict of interest [7].
Independent ethics committees and institutional ethics committees were set up to approve clinical trials. Ethics committees often charge a review fee of Rs 10,000 to Rs 50,000 for considering trials. 97% ethic committees’ members get paid an honorarium [8]. In an interviewDr C M Gulhati the editor of the Monthly Index of Medical Specialties noted that as a ‘commercial concern’ and ‘service provider’ for their clients (the researchers), they have no obligation towards the subjects of the trial themselves [9].
ax reg ulation beg ins to bite
In this exploitative situation, with lax governmental regulation, serious problems have arisen. The Health Minister Ghulam Nabi Azad reported to Parliament that there were 1,725 deaths had among subjects participating in clinical trials over a four-year period (2007-10). The figure went up sharply from 132 in 2007 to 668 in 2010. There was a fall in deaths in 2011 to 438 which has been attributed to a decrease in the total number of trials conducted which fell from 254 in 2010 to 169 in 2011. Of these 1725 only 22 have received any compensation. Compensation was only paid to trial victims who were injured or died in 2010-11, and that after a committee chaired by Maneka Gandhi, Member of Parliament, probed the matter last year. No action has been taken against any pharma company, ethics committee that oversees clinical trials or contract research organisation that conducted the trials [10].
Criticism was expressed from diverse quarters. Justice R M Lodha commented on the situation. “Human beings are being treated as animals. This is unfortunate”, he said. Dr Lalit Kumar an oncologist from All India Institute of Medical Science pointed out that the lack of supervision by Indian health officials has created a culture of impunity among drug research companies and the doctors who work for them [11].
Ethic Committee s and Compensation
The Government has now decided that Ethics Committees must decide compensation. This is indeed unfortunate. The whole matter of causality is complicated and requires great medical expertise.
Many of the persons undergoing trials have an underlying
disease which could well be the cause of death. This allows the
committee to blame ‘other causes’ for any adverse event. The
ethics committee is not equipped to make these evaluations. Even
the ‘Association of Clinical Research Organizations’ (ACRO) which
represents the world’s leading global clinical research organizations
has objected to this, saying that the decision was a backward step
that would make high quality research impossible [12, 13]. They
pointed out that ethics committees lack the scientific and medical
know-how necessary to accurately identify Serious Adverse
Event (SAE) causation and hence the level of compensation. In
addition to medical knowledge they would need to be experts in
law and proficient in actuarial science. Ethics committees are often
associated with the institution where the research is taking place
leading to a conflicts of interest may arise. They have suggested
that an independent body must make the decisions about
compensation. Unfortunately the Central Drugs Standard Control
Organization (CDSCO) has gone ahead without heeding the critics
and developed new guidelines for ethics committees to calculate
compensation [14].
One method of calculating compensation is the multiplier method
used by the claims tribunal under the Motor Vehicle Act 1988 which
is administered by a legal tribunal [13]. This seems a practical way
forward. Another suggestion is that the Government can consider
the United States National Vaccine Injury Compensation model.
This is a “no fault” system which provides compensation to all
legitimate claimants of vaccine injury from tax money. This may
sound attractive because victims now have to go from pillar to post
to prove casualty [15]. The scheme may in fact harm more patients
by making clinical trial organizations more reckless, assured that
they may never have to take blame for any adverse event.
However there is still hope. Trials done in this environment are losing
credibility and beginning to tarnish the image of the pharmaceutical
companies doing trials in India. They have begun to quit India.
Last year out of 118,804 human trials in 178 countries, less than
2,000, or 2%, were done in India compared to 9,352, or 8%, in
neighboring China, according to the US government’s www. web site. India’s current share of 2% is a fraction
of the 15% predicted by lobby group Associated Chambers of
Commerce and Industry of India (Assocham) [16].
This exodus of clinical trials away from India may make the
government realize the folly of its short sighted strategies.The
Government may yet come to realize that it makes long term
economic sense to jealously guard its poor from exploitation by the
pharmaceutical industry. Ultimately it is the duty of the Government
to protect its poor and vulnerable citizens.
[1] Drugs and Cosmetics (3rd Amendment) Rules, 2011 Ministry of Health
and Family Welfare Notification Gazette of India (extraordinary) Part
2, section 3, subsection (1), vide GSR 821 (E) 18 November 2011
available at
gazette/G.S.R.821(E) Accessed on 9/8/12.
[2] Banerjee A. In full run: Clinical trials to hit Rs 1,100 cr in 3 yrs. Economic
Times Nov 17, 2004. Available at http://articles.economictimes.
rabo-india-finance . Accessed on 10/8/12.
[3] Bajpai V, Saraya A. Industry-sponsored clinical research. The National
Medical Journal of India 2011;24:300-1.
[4] Jayaraman KS Outsourcing clinical trials to India rash and risky, critics
warn. Nature Medicine 2004; 10: 440 doi;10.1038/nm0504-440a.
[5] Singh S. Drug Controller of India. Clinical Trials New Horizon – India.
Available at
regulation_legislation/icdra/1_India_ClinicalTrialsNewHorizon.pdf. Accessed
on 10/08/12.
[6] Srinivasan S. Ethical concerns in clinical trials in India: an investigation
Centre for studies in Ethics and Rights. Mumbai February 2009.
Available at
OatJkMri.pdf. Accessed on 11/8/12.
[7] Nagarajan R. Experiments with untruth Times of India July 10, 2011.
council. Accessed on 11/08/12.
[8] Nadig P, Joshi M, Uthappa A. Competence of ethics committees
in patient protection in clinical research. Indian J Med Ethics.
[9] Subir Roy. Clinical trials gone haywire. Business Standard Sunday,
Aug 1, 2012 Available at
storypage.php?autono=481967. Accessed on 1/8/12.
[10] Paliwal A. Drug trials in India killed 2,031 persons Down to Earth Jun
30, 2012.
[11] Murali Krishnan. Clinical trials go wrong in India. Deutsche Welle
[12] MacDonald G. ACRO concerned about ethics committees’ SAE
role under draft Indian rules.Outsourcing 5January
2012. Available at
draft-Indian-rules. Accessed on 17/8/12.
[13] Peddicord D. Comments to “Drugs and Cosmetics (3rd amendment)
Rules 2011. Available at
Accessed on 17/8/12.
[14] CDSCO issues raft guidelines to calculate compensation for victims of
clinical trials. August 07.2012 Available at https://mail. Accessed
on 11/08/12.
[15] Kang G Putting patients first: draft guidelines for compensation for
research-related injury in clinical trials in India. Indian J of Medical
Ethics 2012 ;9: 77-9.
[16] Chandrasekaran A. Clinical trials continue to decline in India. LiveMint
Jan 6,2012
continue-to-de.html. Accessed on 10/08/12.